Quality of Life and Adverse Effects in Epilepsy Patients (EPIKA)

Observational, multicentre, epidemiological study to determine the HRQOL of patients with epilepsy according to treatment sub-group and to validate the Spanish version of the Adverse Events Profile, produced by G. Baker et al. Three treatment groups will be examined: patients receiving only a new anti-epilepsy drug (AED), patients receiving a "classic" AED; patients receiving combination therapy.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Epilepsy Brain Diseases Central Nervous System Diseases Nervous System Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Barcelona, Spain

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Epileptic adult patients treated at a stable dose with one or more AEDs for ≥ 3 months

Exclusion criteria

Symptomatic epilepsy due to malignant brain tumour or progressive brain disease.
Confirmed diagnosis of a concomitant chronic disease

Sponsors and collaborators

Lead sponsor

UCB Pharma

Industry

Registry information

Official study title

Quality of Life and Adverse Effects in Epilepsy Patients According to Treatment Group (EPIKA)

Important dates

Study start: 2006
Primary completion: 2007
Study completion: 2007
First posted: Mar 15, 2006
Registry last updated: Jan 30, 2008

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed